PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer
Journal of Clinical Medicine · 25.07.2023 · 12 (15) · 4882
DOI: 10.3390/jcm12154882 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.07.2023. Verfasst von Jeremy McGale und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Columbia University Medical Center, New York, NY 10032, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
HER2 (Human Epidermal Growth Factor Receptor 2)-positive breast cancer is characterized by amplification of the HER2 gene and is associated with more aggressive tumor growth, increased risk of metastasis, and poorer prognosis when compared to other subtypes of breast cancer. HER2 expression is therefore a critical tumor feature that can be used to diagnose and treat breast cancer. Moving forward, advances in HER2 in vivo imaging, involving the use of techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), may allow for a greater role for HER2 status in guiding the management of breast cancer patients. This will apply both to patients who are HER2-positive and those who have limited-to-minimal immunohistochemical HER2 expression (HER2-low), with imaging ultimately helping clinicians determine the size and location of tumors. Additionally, PET and SPECT could help evaluate effectiveness of HER2-targeted therapies, such as trastuzumab or pertuzumab for HER2-positive cancers, and specially modified antibody drug conjugates (ADC), such as trastuzumab-deruxtecan, for HER2-low variants. This review will explore the current and future role of HER2 imaging in personalizing the care of patients diagnosed with breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Columbia University Medical Center, New York, NY 10032, USA.
- Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.
- Campbell University School of Osteopathic Medicine, Lillington, NC 27546, USA.
- American University of the Caribbean School of Medicine, Cupecoy, Sint Maarten.
- Touro College of Osteopathic Medicine, Middletown, NY 10940, USA.
ORCID-Profile: Phuong Duong, Laurent Dercle, Romain-David Seban
Förderung
- NCI NIH HHS
Zitieren
APA
McGale, J., Khurana, S., Huang, A., Roa, T., Yeh, R., Shirini, D., Doshi, P., Nakhla, A., Bebawy, M., Khalil, D., Lotfalla, A., Higgins, H., Gulati, A., Girard, A., Bidard, F. C., Champion, L., Duong, P., Dercle, L., & Seban, R. D. (2023). PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer. Journal of Clinical Medicine, 12(15), 4882. https://doi.org/10.3390/jcm12154882
Vancouver
McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D, et al. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer. Journal of Clinical Medicine. 2023;12(15):4882. doi:10.3390/jcm12154882
BibTeX
@article{McGale2023,
author = {McGale, Jeremy and Khurana, Sakshi and Huang, Alice and Roa, Tina and Yeh, Randy and Shirini, Dorsa and Doshi, Parth and Nakhla, Abanoub and Bebawy, Maria and Khalil, David and Lotfalla, Andrew and Higgins, Hayley and Gulati, Amit and Girard, Antoine and Bidard, Francois-Clement and Champion, Laurence and Duong, Phuong and Dercle, Laurent and Seban, Romain-David},
title = {PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {15},
pages = {4882},
doi = {10.3390/jcm12154882}
}
EUVIMED